• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

配体修饰纳米载体在动脉粥样硬化治疗中的进展。

Advances in the treatment of atherosclerosis with ligand-modified nanocarriers.

作者信息

Deng Xiujiao, Wang Jinghao, Yu Shanshan, Tan Suiyi, Yu Tingting, Xu Qiaxin, Chen Nenghua, Zhang Siqi, Zhang Ming-Rong, Hu Kuan, Xiao Zeyu

机构信息

Department of Pharmacy The First Affiliated Hospital of Jinan University Guangzhou China.

The Guangzhou Key Laboratory of Basic and Translational Research on Chronic Diseases Jinan University Guangzhou China.

出版信息

Exploration (Beijing). 2023 Dec 7;4(3):20230090. doi: 10.1002/EXP.20230090. eCollection 2024 Jun.

DOI:10.1002/EXP.20230090
PMID:38939861
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11189587/
Abstract

Atherosclerosis, a chronic disease associated with metabolism, poses a significant risk to human well-being. Currently, existing treatments for atherosclerosis lack sufficient efficiency, while the utilization of surface-modified nanoparticles holds the potential to deliver highly effective therapeutic outcomes. These nanoparticles can target and bind to specific receptors that are abnormally over-expressed in atherosclerotic conditions. This paper reviews recent research (2018-present) advances in various ligand-modified nanoparticle systems targeting atherosclerosis by specifically targeting signature molecules in the hope of precise treatment at the molecular level and concludes with a discussion of the challenges and prospects in this field. The intention of this review is to inspire novel concepts for the design and advancement of targeted nanomedicines tailored specifically for the treatment of atherosclerosis.

摘要

动脉粥样硬化是一种与代谢相关的慢性疾病，对人类健康构成重大风险。目前，现有的动脉粥样硬化治疗方法效率不足，而表面改性纳米颗粒的应用有望带来高效的治疗效果。这些纳米颗粒可以靶向并结合在动脉粥样硬化状态下异常过度表达的特定受体。本文综述了近期（2018年至今）各种靶向动脉粥样硬化的配体修饰纳米颗粒系统的研究进展，这些系统通过特异性靶向标志性分子，以期在分子水平上实现精准治疗，并在最后讨论了该领域的挑战与前景。本综述旨在为专门用于治疗动脉粥样硬化的靶向纳米药物的设计和发展激发新的理念。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f690/11189587/0a9628f74e05/EXP2-4-20230090-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f690/11189587/58d2a83a01a0/EXP2-4-20230090-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f690/11189587/2ae79af4803f/EXP2-4-20230090-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f690/11189587/2f975340ce4c/EXP2-4-20230090-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f690/11189587/6f34d2cef324/EXP2-4-20230090-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f690/11189587/cf4d56e8c573/EXP2-4-20230090-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f690/11189587/0a9628f74e05/EXP2-4-20230090-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f690/11189587/58d2a83a01a0/EXP2-4-20230090-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f690/11189587/2ae79af4803f/EXP2-4-20230090-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f690/11189587/2f975340ce4c/EXP2-4-20230090-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f690/11189587/6f34d2cef324/EXP2-4-20230090-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f690/11189587/cf4d56e8c573/EXP2-4-20230090-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f690/11189587/0a9628f74e05/EXP2-4-20230090-g009.jpg

相似文献

1
Advances in the treatment of atherosclerosis with ligand-modified nanocarriers.配体修饰纳米载体在动脉粥样硬化治疗中的进展。
Exploration (Beijing). 2023 Dec 7;4(3):20230090. doi: 10.1002/EXP.20230090. eCollection 2024 Jun.
2
Surface-modified nanotherapeutics targeting atherosclerosis.针对动脉粥样硬化的表面修饰纳米治疗药物。
Biomater Sci. 2022 Sep 27;10(19):5459-5471. doi: 10.1039/d2bm00660j.
3
Molecularly targeted nanomedicine enabled by inorganic nanoparticles for atherosclerosis diagnosis and treatment.无机纳米颗粒实现的分子靶向纳米医学用于动脉粥样硬化的诊断和治疗。
Adv Drug Deliv Rev. 2023 Mar;194:114709. doi: 10.1016/j.addr.2023.114709. Epub 2023 Jan 20.
4
A review of the current scientific and regulatory status of nanomedicines and the challenges ahead.纳米药物的当前科学与监管现状及未来挑战综述。
PDA J Pharm Sci Technol. 2011 Mar-Apr;65(2):177-95.
5
Targeted Delivery of Nanoparticles to Blood Vessels for the Treatment of Atherosclerosis.纳米颗粒靶向递送至血管用于治疗动脉粥样硬化
Biomedicines. 2024 Jul 6;12(7):1504. doi: 10.3390/biomedicines12071504.
6
Chlorin e6 (Ce6)-loaded plaque-specific liposome with enhanced photodynamic therapy effect for atherosclerosis treatment.载有氯乙啶 6（Ce6）的斑块特异性脂质体，用于增强动脉粥样硬化治疗的光动力疗法效果。
Talanta. 2023 Dec 1;265:124772. doi: 10.1016/j.talanta.2023.124772. Epub 2023 Jun 9.
7
Nanotechnology: an evidence-based analysis.纳米技术：基于证据的分析。
Ont Health Technol Assess Ser. 2006;6(19):1-43. Epub 2006 Nov 1.
8
Tumor-targeting delivery of herb-based drugs with cell-penetrating/tumor-targeting peptide-modified nanocarriers.基于细胞穿透/肿瘤靶向肽修饰的纳米载体实现草药药物的肿瘤靶向递释。
Int J Nanomedicine. 2018 Mar 9;13:1425-1442. doi: 10.2147/IJN.S156616. eCollection 2018.
9
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.癌症的先进靶向疗法：药物纳米载体，化疗的未来。
Eur J Pharm Biopharm. 2015 Jun;93:52-79. doi: 10.1016/j.ejpb.2015.03.018. Epub 2015 Mar 23.
10
Directing Cell Delivery to Murine Atherosclerotic Aortic Lesions via Targeting Inflamed Circulatory Interface using Nanocarriers.通过使用纳米载体靶向炎症循环界面将细胞递送至小鼠动脉粥样硬化主动脉病变处。
bioRxiv. 2024 Feb 5:2024.02.02.578719. doi: 10.1101/2024.02.02.578719.

引用本文的文献

1
Recent Advances in Nanozymes for the Treatment of Atherosclerosis.用于治疗动脉粥样硬化的纳米酶的最新进展
Int J Nanomedicine. 2025 Jul 29;20:9447-9472. doi: 10.2147/IJN.S540010. eCollection 2025.
2
NIR light-propelled Janus Polydopamine@Mesoporous silica gene delivery nanomotor for the enhanced gene treatment of critical limb ischemia.近红外光驱动的Janus聚多巴胺@介孔二氧化硅基因递送纳米马达用于增强严重肢体缺血的基因治疗
Mater Today Bio. 2025 Jun 6;33:101950. doi: 10.1016/j.mtbio.2025.101950. eCollection 2025 Aug.
3
Metabolic Features and Nutritional Interventions in Chronic Diseases.

本文引用的文献

1
Biomimetic nanomedicines for precise atherosclerosis theranostics.用于精准动脉粥样硬化诊疗的仿生纳米药物
Acta Pharm Sin B. 2023 Nov;13(11):4442-4460. doi: 10.1016/j.apsb.2022.11.014. Epub 2022 Nov 15.
2
Nanozyme for tumor therapy: Surface modification matters.用于肿瘤治疗的纳米酶：表面修饰至关重要。
Exploration (Beijing). 2021 Sep 1;1(1):75-89. doi: 10.1002/EXP.20210005. eCollection 2021 Aug.
3
Recent applications of immunomodulatory biomaterials for disease immunotherapy.免疫调节生物材料在疾病免疫治疗中的最新应用。
慢性病的代谢特征与营养干预
Nutrients. 2025 May 28;17(11):1826. doi: 10.3390/nu17111826.
4
Targeted drug delivery systems for atherosclerosis.用于动脉粥样硬化的靶向给药系统。
J Nanobiotechnology. 2025 Apr 23;23(1):306. doi: 10.1186/s12951-025-03384-0.
5
The Potential of RNA Therapeutics in Treating Cardiovascular Disease.RNA疗法在治疗心血管疾病中的潜力。
Drugs. 2025 May;85(5):659-676. doi: 10.1007/s40265-025-02173-1. Epub 2025 Apr 2.
6
Dual-mode-driven nanomotors targeting inflammatory macrophages for the MRI and synergistic treatment of atherosclerosis.用于磁共振成像及协同治疗动脉粥样硬化的靶向炎症巨噬细胞的双模式驱动纳米马达
J Nanobiotechnology. 2025 Jan 29;23(1):54. doi: 10.1186/s12951-025-03136-0.
7
Deciphering Structural Dynamics of Atherosclerosis Proteins: Insights from Phytochemicals that Interceded Functional and Structural Changes in Targeted Atherosclerotic Proteins.解读动脉粥样硬化蛋白质的结构动力学：来自植物化学物质的见解，这些物质介导了靶向动脉粥样硬化蛋白质的功能和结构变化。
ACS Omega. 2024 Nov 23;9(49):48159-48172. doi: 10.1021/acsomega.4c04975. eCollection 2024 Dec 10.
8
Nanocarriers for targeted drug delivery in the vascular system: focus on endothelium.纳米载体在血管系统中靶向药物递送的应用：聚焦于内皮细胞。
J Nanobiotechnology. 2024 Oct 12;22(1):620. doi: 10.1186/s12951-024-02892-9.
9
Tumor specific in situ synthesis of therapeutic agent for precision cancer therapy.肿瘤特异性原位合成治疗剂用于精准癌症治疗。
J Nanobiotechnology. 2024 Oct 10;22(1):612. doi: 10.1186/s12951-024-02825-6.
10
Thermosensitive Hydrogel with Programmable, Self-Regulated HIF-1α Stabilizer Release for Myocardial Infarction Treatment.用于心肌梗死治疗的具有可编程、自调节缺氧诱导因子-1α稳定剂释放功能的热敏水凝胶
Adv Sci (Weinh). 2024 Nov;11(43):e2408013. doi: 10.1002/advs.202408013. Epub 2024 Sep 23.
Exploration (Beijing). 2022 May 23;2(6):20210157. doi: 10.1002/EXP.20210157. eCollection 2022 Dec.
4
Mobile mechanical signal generator for macrophage polarization.用于巨噬细胞极化的移动机械信号发生器
Exploration (Beijing). 2023 Apr 3;3(2):20220147. doi: 10.1002/EXP.20220147. eCollection 2023 Apr.
5
Advanced strategies to evade the mononuclear phagocyte system clearance of nanomaterials.逃避单核吞噬细胞系统对纳米材料清除的先进策略。
Exploration (Beijing). 2023 Jan 5;3(1):20220045. doi: 10.1002/EXP.20220045. eCollection 2023 Feb.
6
MC3/SAINT-O-Somes, a novel liposomal delivery system for efficient and safe delivery of siRNA into endothelial cells.MC3/SAINT-O-Somes，一种新型脂质体递药系统，可高效、安全地将 siRNA 递送至内皮细胞。
J Liposome Res. 2023 Dec;33(4):328-337. doi: 10.1080/08982104.2023.2187821. Epub 2023 Mar 15.
7
Duplex Responsive Nanoplatform with Cascade Targeting for Atherosclerosis Photoacoustic Diagnosis and Multichannel Combination Therapy.具有级联靶向的双响应纳米平台用于动脉粥样硬化光声诊断和多通道联合治疗。
Adv Mater. 2023 May;35(21):e2300439. doi: 10.1002/adma.202300439. Epub 2023 Mar 31.
8
MiR-146a encapsulated liposomes reduce vascular inflammatory responses through decrease of ICAM-1 expression, macrophage activation, and foam cell formation.载 miR-146a 脂质体通过降低 ICAM-1 表达、减少巨噬细胞活化和泡沫细胞形成，减轻血管炎症反应。
Nanoscale. 2023 Feb 16;15(7):3461-3474. doi: 10.1039/d2nr03280e.
9
Minimalist Nanocomplex with Dual Regulation of Endothelial Function and Inflammation for Targeted Therapy of Inflammatory Vascular Diseases.具有内皮功能和炎症双重调节作用的极简纳米复合物，用于炎症性血管疾病的靶向治疗。
ACS Nano. 2023 Feb 14;17(3):2761-2781. doi: 10.1021/acsnano.2c11058. Epub 2023 Jan 31.
10
Molecularly targeted nanomedicine enabled by inorganic nanoparticles for atherosclerosis diagnosis and treatment.无机纳米颗粒实现的分子靶向纳米医学用于动脉粥样硬化的诊断和治疗。
Adv Drug Deliv Rev. 2023 Mar;194:114709. doi: 10.1016/j.addr.2023.114709. Epub 2023 Jan 20.